New research highlights wide variation in prostate cancer testing between GP practices
Peer-Reviewed Publication
Updates every hour. Last Updated: 14-May-2025 00:10 ET (14-May-2025 04:10 GMT/UTC)
A largescale study has found huge variation between GP practices on whether they are likely to pick up prostate cancer using a blood test.
In metastatic cancer surveillance, monitoring the actual concentrations of circulating tumor DNA (ctDNA) may be critical. Researchers showed that absolute ctDNA concentration thresholds can be defined to rule out or predict impending cancer progression. They introduce a dual threshold model in a novel study in The Journal of Molecular Diagnostics, published by Elsevier, that may improve cancer surveillance, patient stratification, and risk-informed, personalized treatment by providing more accurate and timely assessment of disease progression.
Researchers have developed a cancer vaccine method that can target virtually any solid tumor, amplifying the visibility of tumor antigens to the immune system, leading to a potent response. Preclinical tests shows that it helps slow or stop the progression of melanoma, triple-negative breast cancer, lung and ovarian cancer
The Technion researchers’ paper reveals the answer through a phenomenon they discovered: the key to nanoparticle transport across the intestinal wall lies in breast milk proteins, which create an effect that named by the Technion scientists - Human Breast Milk Protein Corona. This "corona" forms a protein coating around the nanoparticle, allowing it to pass through the intestinal layers, and depends on the nanoparticles’ charge. The researchers confirmed their findings in both human intestinal cell line and pig intestinal samples.